Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Elder Pharmaceuticals Ltd

    Elder Pharmaceuticals Ltd, a Mumbai based pharmaceutical company commenced operations in 1989.

    Elder Pharmaceuticals principal activities include the manufacturing and m

  • No Image
    Embark Lifescience Pvt Ltd

    Embark Lifescience Pvt Ltd is an Indian health care company incorporated in 2005 with its head office and manufacturing unit is located in Roorkee, Uttarakhand. Mr. Suresh Lal S

  • No Image
    Emcure Pharmaceuticals Ltd

    Emcure Pharmaceuticals Ltd was incorporated in April 1981 by Mr Satish Mehta and is engaged in the manufacturing of formulations and Active Pharma Ingredients (API). The company

  • No Image
    Enaltec Labs Pvt Ltd

    Enaltec Labs Pvt Ltd is engaged in manufacturing and trading of active pharmaceutical ingredients (API?s). Furthermore, over the years, ELPL has moved towards providing end to e